Equities research analysts at BTIG Research assumed coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $35.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 79.67% from the company’s current price.
Shares of Y-mAbs Therapeutics stock opened at $19.48 on Tuesday. Y-mAbs Therapeutics has a 52-week low of $19.20 and a 52-week high of $31.00.
In related news, Director Ashu Tyagi bought 430,174 shares of Y-mAbs Therapeutics stock in a transaction on Tuesday, September 25th. The stock was acquired at an average price of $16.00 per share, with a total value of $6,882,784.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Moller San Pedro Claus Juan bought 31,250 shares of Y-mAbs Therapeutics stock in a transaction on Tuesday, September 25th. The shares were bought at an average cost of $16.00 per share, with a total value of $500,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 961,424 shares of company stock worth $15,382,784 over the last 90 days.
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Recommended Story: Conference Calls
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.